Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Neurofibromatosis 2: early-phase trial registry
1 of 4 indexed Neurofibromatosis 2 trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 1 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Neurofibromatosis 2: 4 US clinical trials tracked, 1 recruiting.
Neurofibromatosis 2 is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is FDA Office of Orphan Products Development, running 1 of these trials.
Enrollment posture brief
Registry condition neurofibromatosis-2
OPEN 1 | RECR 25% | LATE 0 | EARLY 3 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Cancer (25% recruiting · 8 trials)
Neurofibromatosis 2 lists 1 open slots (25% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Neurofibromatosis 2 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Neurofibromatosis 2 is recruiting below its size-band peers.
1 of 4 indexed trials (25%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
Neurofibromatosis (NF) Registry Portal
The Children's Tumor Foundation
NCT01885767
Study of Aspirin in Patients With Vestibular Schwannoma
Massachusetts Eye and Ear Infirmary
NCT03079999
AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas
Massachusetts General Hospital
NCT02831257
An Implant for Hearing Loss Due to Removal of Neurofibromatosis 2 Tumors
FDA Office of Orphan Products Development
NCT00030043
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Neurofibromatosis 2 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Neurofibromatosis 2 trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Neurofibromatosis 2 page
4 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Neurofibromatosis 2 trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- FDA Office of Orphan Products Development sponsors the most Neurofibromatosis 2 trials on record, review their full trial history before evaluating a specific study. See FDA Office of Orphan Products Development's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Neurofibromatosis 2 condition card totals 4 registered trials; most-linked intervention AZD2014; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.